133 related articles for article (PubMed ID: 38512604)
1. Letter to the Editor: Comment on: "BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma".
Yu ST; Lei ST
Ann Surg Oncol; 2024 Jun; 31(6):3737-3738. PubMed ID: 38512604
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Is BRAF V600E Mutation Associated with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma?
Lai HF; Hang JF; Chen JY
Ann Surg Oncol; 2024 Jun; 31(6):3974-3975. PubMed ID: 38366182
[No Abstract] [Full Text] [Related]
3. Evaluation of the expression levels of BRAF
Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
[TBL] [Abstract][Full Text] [Related]
4. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].
Wang J; Liu LT; Cui D; He L; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264
[No Abstract] [Full Text] [Related]
5. Incidence of
Kure S; Ishino K; Kudo M; Wada R; Saito M; Nagaoka R; Sugitani I; Naito Z
J Int Med Res; 2019 Nov; 47(11):5560-5572. PubMed ID: 31533501
[TBL] [Abstract][Full Text] [Related]
6. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
[TBL] [Abstract][Full Text] [Related]
8. An Animal Model Further Uncovers the Role of Mutant Braf
Koelsch B; Theurer S; Staniszewska M; Heupel J; Koch A; Mergener S; Walk F; Fischer C; Kutritz A; Schmid KW; Kindler-Röhrborn A
Am J Pathol; 2020 Mar; 190(3):702-710. PubMed ID: 31953036
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between BRAF
Zhou B; Hei H; Li YQ; Zhang DY; Wang DQ; Qin JW
Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(14):1060-1063. PubMed ID: 37032157
[TBL] [Abstract][Full Text] [Related]
12. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
13. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
14. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Ito Y; Yoshida H; Maruo R; Morita S; Takano T; Hirokawa M; Yabuta T; Fukushima M; Inoue H; Tomoda C; Kihara M; Uruno T; Higashiyama T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
Endocr J; 2009; 56(1):89-97. PubMed ID: 18840924
[TBL] [Abstract][Full Text] [Related]
16. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
[TBL] [Abstract][Full Text] [Related]
17. Letter to the Editor From Boucai and Tuttle: "BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-Associated Mortality Risk in Papillary Thyroid Cancer".
Boucai L; Tuttle RM
J Clin Endocrinol Metab; 2022 May; 107(6):e2638-e2639. PubMed ID: 35262726
[No Abstract] [Full Text] [Related]
18. A mutation panel comprising BRAF
Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
[TBL] [Abstract][Full Text] [Related]
19. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population.
Liu S; Zhang B; Zhao Y; Chen P; Ji M; Hou P; Shi B
Int J Clin Exp Pathol; 2014; 7(10):6922-8. PubMed ID: 25400776
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
